Fezakinumab

Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]

Fezakinumab
Monoclonal antibody
TypeWhole antibody
TargetIL-22
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6408H9873N1706O2016S44
Molar mass143.87 kg/mol g·mol−1
 NY (what is this?)  (verify)

Research and development

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data was not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]

References
  1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. Retrieved 2017-06-07.
  2. "Archived copy" (PDF). Archived from the original (PDF) on 2011-09-04. Retrieved 2012-09-25.CS1 maint: archived copy as title (link)
  3. "Living Medical eTextbook - Rheumatology - Projects In Knowledge - Rheumatoid Arthritis Edition Table of Contents - Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Lmt.projectsinknowledge.com. p. 4. Retrieved 2017-06-07.
  4. Richardson, Brian. "Atopic dermatitis: fezakinumab shows benefit in severe disease". quantiamd.univadis.com. Aptus Health. Retrieved 24 January 2018.

javascript:void(0);

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.